瘤爆发反应对epcoritamab治疗的病理景观
Osamu Imataki1, Makiko Uemura2, Haruyuki Fujita2
1Faculty of Medicine, Division of Hematology, Department of Internal Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan. imataki.osamu@kagawa-u.ac.jp.
International journal of hematology
|August 12, 2024
概括
瘤爆发反应 (TFR) 是免疫治疗期间的炎症反应,可以模仿疾病的进展. 这项案例研究强调了TFR作为扩散大B细胞淋巴瘤中对epcoritamab的积极反应的潜在指标.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 皮肤病学 皮肤病学
背景情况:
- 瘤爆发反应 (TFR) 在免疫治疗期间呈现为病变大小增加,通常被误认为是疾病进展.
- TFR表示瘤部位炎症,通常在免疫治疗中观察到,称为瘤伪进展.
- 目前尚不完全了解TFR背后的精确机制.
研究的目的:
- 报告患有复发性/耐药性扩散性大B细胞淋巴瘤患者的TFR病例,该患者接受了epcoritamab治疗.
- 描述TFR的临床表现,管理和组织病理学发现.
- 强调TFR作为治疗反应标志物的潜在意义.
主要方法:
- 一名62岁的男性患有复发性/耐药性扩散性大B细胞淋巴瘤,接受了epcoritamab.
- 通过病变胀确定了TFR,并通过静脉注射德甲来管理.
- 30日皮肤活检分析了他的病理学,包括CD标志物.
主要成果:
- 患者经历了epcoritamab注射后的TFR,其特点是胀的皮肤淋巴瘤病变.
- 用德甲成功控制了TFR,并继续治疗epcoritamab.
- 组织病理学发现CD20+淋巴细胞被CD4+和CD8+T细胞包围,CD8+占主导地位.
结论:
- 瘤爆发反应虽然很少发生,但可能表明对epcoritamab治疗有良好的反应.
- 有可能对TFR进行不充分的诊断;识别其临床病理特征对于管理至关重要.
- 对TFR机制和在epcoritamab治疗中的重要性进行进一步的研究是有必要的.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.9K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
